A5028232370- Neonatal and Maternal Infections
- Neonatal Health and Biochemistry
- Neonatal and fetal brain pathology
- Metabolism and Genetic Disorders
- Central Venous Catheters and Hemodialysis
- Advanced MRI Techniques and Applications
- Neonatal Respiratory Health Research
- Infectious Encephalopathies and Encephalitis
- Streptococcal Infections and Treatments
- Antibiotics Pharmacokinetics and Efficacy
- Fetal and Pediatric Neurological Disorders
- Congenital Heart Disease Studies
- Neonatal skin health care
- Cardiovascular Conditions and Treatments
- Antimicrobial Resistance in Staphylococcus
- Urological Disorders and Treatments
- Kidney Stones and Urolithiasis Treatments
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Cardiovascular Issues in Pregnancy
- Antifungal resistance and susceptibility
- Salmonella and Campylobacter epidemiology
- Emergency and Acute Care Studies
- Renal function and acid-base balance
- Sepsis Diagnosis and Treatment
- interferon and immune responses
Medway Maritime Hospital
2014-2024
Medway NHS Foundation Trust
2015-2024
Norfolk and Norwich University Hospitals NHS Foundation Trust
2023
Cambridge University Hospitals NHS Foundation Trust
2008
Addenbrooke's Hospital
2007-2008
Rosie Hospital
2007
In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials promising neuroprotectants slow expensive. We aimed to determine accuracy thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as predictors neurodevelopmental abnormalities observed encephalopathy.We did a prospective multicentre cohort study across eight intensive care units in UK USA,...
To describe the epidemiology of neonatal infection over past decade in UK units.Retrospective analysis prospectively collected surveillance network data from 2005 to 2014.30 units UK.Newborns on participating who had a positive blood, cerebrospinal fluid or urine culture and were treated with at least 5 days appropriate antibiotics.2171 episodes 1922 infants recorded. The incidence was 6.1/1000 live births 48.8/1000 admissions (2.9 23.5 respectively if coagulase-negative staphylococci (CoNS)...
Importance Although whole-body hypothermia is widely used after mild neonatal hypoxic-ischemic encephalopathy (HIE), safety and efficacy have not been evaluated in randomized clinical trials (RCTs), to our knowledge. Objective To examine the effect of 48 72 hours HIE on cerebral magnetic resonance (MR) biomarkers. Design, Setting, Participants This open-label, 3-arm RCT was conducted between October 31, 2019, April 28, 2023, with masked outcome analysis. were neonates at 6 tertiary intensive...
Sepsis and bacterial meningitis are major causes of mortality morbidity in neonates infants. Meropenem, a broad-spectrum antibiotic, is not licensed for use infants below 3 months age sufficient information on its plasma CSF disposition dosing lacking. To determine pharmacokinetics meropenem young the link between clinical outcomes babies with late-onset sepsis (LOS). Data were collected two recently conducted studies, i.e. NeoMero-1 (neonatal LOS) NeoMero-2 meningitis). Optimally timed...
To define the susceptibilities of common causative pathogens neonatal sepsis in UK.Retrospective analysis prospectively collected neonIN infection surveillance network data between 2005 and 2014.30 units UK.Newborns admitted to participating who return a positive blood, cerebrospinal fluid or urine culture are treated with at least 5 days appropriate antibiotics.1568 isolates recorded antimicrobial were including 328 early-onset (EOS) 1240 late-onset (LOS) isolates. The majority EOS (>92%)...
<h3>Introduction</h3> Despite cooling, adverse outcomes are seen in up to half of the surviving infants after neonatal encephalopathy. A number novel adjunct drug therapies with cooling have been shown be highly neuroprotective animal studies, and currently awaiting clinical translation. Rigorous evaluation these phase II trials using surrogate MR biomarkers may speed their bench bedside recent systematic review single-centre studies has suggested that spectroscopy offer best promise;...
<b><i>Background:</i></b> Variable responses to hypothermic neuroprotection are related the clinical heterogeneity of encephalopathic babies; hence better disease stratification may facilitate development individualized neuroprotective therapies. <b><i>Objectives:</i></b> We examined if whole blood gene expression analysis can identify specific transcriptome profiles in neonatal encephalopathy. <b><i>Material and...
Objective Catheter-related sepsis (CRS) is a major complication with significant morbidity and mortality. Evidence lacking regarding the most appropriate antiseptic for skin disinfection before percutaneous central venous catheter (PCVC) insertion in preterm neonates. To inform feasibility design of definitive randomised controlled trial (RCT) two formulations, we conducted Antiseptic Randomised Controlled Trial Insertion Catheters (ARCTIC) study to assess colonisation, sepsis, morbidity....
Near-patient testing of blood sugar, bilirubin, and hematocrit (Hct) has been performed for many years on neonatal intensive care units. The aim this study was to compare traditional measurements using Ascensia Elite XL Blood Glucometers, bilimeters, Hct readers with the Roche OMNI-S analyzer. Simultaneous samples were collected gas machine analysis (maximum, 200 μL) centrifuged capillary (150 standard analysis. Between 80 168 each made serum bilirubin (n = 113), 168), glucose 100), sodium...
Background: Point-of-care (POC) testing is widely used in neonatal intensive care units and allows increasing numbers of assays to be performed immediately on smaller volumes blood. The use these systems simplifies staff training reduces maintenance costs blood sampling. We initially trialed the Roche OMNI-S analyzer (Roche Diagnostics, Burgess Hill, United Kingdom) late 2003 alongside existing POC equipment laboratory assays. aim this study was assess clinical impact formal introduction...
<h3>Background</h3> Although cerebral metabolic changes during neonatal encephalopathy (NE) have been well characterised using magnetic resonance spectroscopy (MRS) in single-centre studies, the widespread effect of therapeutic hypothermia is less clear. <h3>Objective</h3> To describe patterns brain injury a prospective multi-centre cohort infants with NE who had rescue hypothermic neuroprotection. <h3>Design</h3> After MRS harmonisation on 3T MR scanners (Phillips, GE, Siemens), at six...
<h3>Background</h3> Early cerebral proton magnetic resonance spectroscopy (MRS) predicts medium-term outcomes in neonatal encephalopathy (NE). Metabolite peak-area ratios are most commonly used for prognosis, but conflate pathological information from different metabolites. N-acetylaspartate (NAA) is predominantly neuronal and loss should result reduced NAA absolute-concentration ([NAA]). Thus, thalamic [NAA] offer significant prognostic value difficult to measure a clinical setting. We have...
<h3>Aim</h3> To estimate the incidence of CABSI and effect implementing Matching Michigan care bundle. <h3>Method</h3> Retrospective analysis rates in all neonates with central lines. The reported have varied between 3.2 to 21.8/ 1000 catheter days.<sup>1</sup> NNAP data on 1.8–3.1/1000 is low due underreporting.<sup>2</sup> We at medway had signed up for project aimed reducing CABSI. established our baseline 13.6/1000 days snap shot audit before 2011 been below 10/1000 three consecutive...
<h3>Introduction</h3> Survival of extreme preterm babies born between 22–25 weeks gestation and their disability free survival have increased from 1995 to 2006 in England; however neonatal morbidity has not changed significantly. There is paucity information about the outcome these presence complex congenital heart disease (CHD). <h3>Aim study</h3> To find out prevalence CHD this hospital with a gestational age 22+0 -25+6 during 01 Apr 2008 31 Mar 2015 also determine survival, short long...
s: Critical and Point-of-Care Testing: Managing Technology for the Benefit of All Populations: 22nd International Symposium: September 17-20, 2008: Catalonia Barcelona Plaza Hotel|Barcelona, Spain